Lawson Macartney - Apr 17, 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Director
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Apr 17, 2023
Transactions value $
-$249,432
Form type
4
Date filed
4/18/2023, 07:10 PM
Previous filing
Jan 4, 2023
Next filing
Apr 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $166K +20.8K +43.34% $8.00 68.8K Apr 17, 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale -$416K -20.8K -30.23% $20.00 48K Apr 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -20.8K -100% $0.00* 0 Apr 17, 2023 Common Stock 20.8K $8.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
F2 100% of the shares subject to the option vested on May 26, 2016, the date of the Issuer's first Annual Meeting of Stockholders following the date of grant.